Skip to content
AiSeekAiSeek
Sign in
NewMarketsReported 2026-10-07 18:16

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at NANETS Symposium

Perspective Therapeutics, a radiopharmaceutical company, has had data from its [212Pb]VMT-α-NET program accepted for presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium, highlighting ongoing research on a treatment for neuroendocrine tumors.

Why it matters. Investors and medical professionals will gain insights into the efficacy and safety of the [212Pb]VMT-α-NET treatment for neuroendocrine tumors.

01

Who it touches

  1. 1Perspective Therapeutics, Inc.
  2. manufactures →Fact
    2Clinical drug product candidatesProduct
  3. uses →Fact
    3Lead-212Material
  4. uses →Fact
    4Lead-212 (²¹²Pb)Material
  5. uses →Fact
    5Radium-224/Lead-212 generator platformTechnology
02

Evidence

  • GGlobeNewswire public company newsCompany2026-10-07 18:16
    The Company has proprietary technology that utilizes the alpha-generating isotope <sup>212</sup>Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
    View source
  • GGlobeNewswire public company newsCompany2026-10-07 18:16
    The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).
    View source
  • GGlobeNewswire public company newsCompany2026-10-07 18:16
    The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary <sup>224</sup>Ra/<sup>212</sup>Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candi…
    View source
  • GGlobeNewswire public company newsCompany2026-10-07 18:16
    SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that d…
    View source
  • GGlobeNewswire public company newsCompany2026-10-07 18:16
    Perspective designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion s…
    View source